PMID- 28971268
OWN - NLM
STAT- MEDLINE
DCOM- 20190225
LR  - 20200306
IS  - 1573-0646 (Electronic)
IS  - 0167-6997 (Linking)
VI  - 36
IP  - 3
DP  - 2018 Jun
TI  - Phase I study of the combination of quinacrine and erlotinib in patients with 
      locally advanced or metastatic non small cell lung cancer.
PG  - 435-441
LID - 10.1007/s10637-017-0515-3 [doi]
AB  - Introduction Preclinical data suggest quinacrine acts as an inhibitor of FACT 
      (facilitates chromatin transcription) complex, which may play a role in TKI 
      (tyrosine kinase inhibitor) resistance. The aim of this Phase I study was to 
      study the safety and assess the maximum tolerated dose of quinacrine in 
      combination with erlotinib in non small cell lung cancer (NSCLC). Methods This 
      was a phase I study with standard 3 + 3 dose escalation design with the primary 
      aim of determining the maximum tolerated dose. Two of 3 patients enrolled at dose 
      level 1 experienced dose limiting toxicity (DLT). The next 6 patients were 
      enrolled at dose level - 1 and none of these 6 patients experienced DLT. The dose 
      of 50 mg of quinacrine every other day with 150 mg of erlotinib was established 
      as the maximum tolerated and the recommended phase II dose. One of 3 patients 
      treated at dose level 1 had stable disease. One of 6 patients treated at dose 
      level - 1 had partial response for 6 months, the rest had progressive disease at 
      the time of first assessment. Conclusion Combination of quinacrine and erlotinib 
      was well tolerated but showed limited efficacy in advanced NSCLC.
FAU - Bhateja, Priyanka
AU  - Bhateja P
AUID- ORCID: 0000-0001-9515-0498
AD  - Division of Hematology and Oncology, University Hospitals Cleveland Medical 
      Center, Cleveland, OH, 44106, USA. Priyanka.bhateja@uhhospitals.org.
AD  - Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, 
      44106, USA. Priyanka.bhateja@uhhospitals.org.
FAU - Dowlati, Afshin
AU  - Dowlati A
AD  - Division of Hematology and Oncology, University Hospitals Cleveland Medical 
      Center, Cleveland, OH, 44106, USA.
AD  - Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, 
      44106, USA.
FAU - Sharma, Neelesh
AU  - Sharma N
AD  - Novartis Institute of Biomedical Research, Novartis Pharmaceuticals Corporation, 
      One Health Plaza, East Hanover, NJ, 07936-1080, USA.
LA  - eng
GR  - Early Phase Clinical Research Support/Case Comprehensive Cancer Center, Case 
      Western Reserve University/International
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20171002
PL  - United States
TA  - Invest New Drugs
JT  - Investigational new drugs
JID - 8309330
RN  - 0 (Antineoplastic Agents)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - H0C805XYDE (Quinacrine)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/adverse effects/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/*pathology
MH  - Erlotinib Hydrochloride/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/*pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Quinacrine/adverse effects/*therapeutic use
OTO - NOTNLM
OT  - Erlotinib
OT  - NF-KB
OT  - Non small cell lung cancer
OT  - Phase I
OT  - Quinacrine
EDAT- 2017/10/04 06:00
MHDA- 2019/02/26 06:00
CRDT- 2017/10/04 06:00
PHST- 2017/08/08 00:00 [received]
PHST- 2017/09/22 00:00 [accepted]
PHST- 2017/10/04 06:00 [pubmed]
PHST- 2019/02/26 06:00 [medline]
PHST- 2017/10/04 06:00 [entrez]
AID - 10.1007/s10637-017-0515-3 [pii]
AID - 10.1007/s10637-017-0515-3 [doi]
PST - ppublish
SO  - Invest New Drugs. 2018 Jun;36(3):435-441. doi: 10.1007/s10637-017-0515-3. Epub 
      2017 Oct 2.